Concordia could be an inversion target; MiRagen re-ups with Servier;

@FierceBiotech: This week's Chutes & Ladders: Former Avila CEO Bosley signs on to lead MA's Editas. Report | Follow @FierceBiotech

@JohnCFierce: Seriously, who in their right mind would buy Eli Lilly? They don't need protection. Story | Follow @JohnCFierce

@DamianFierce: I went to BIO 2014 and talked to people about the state of partnering. Article | Follow @DamianFierce

@EmilyMFierce: WHO calls 11-nation meeting over Ebola crisis in west Africa. More | Follow @EmilyMFierce

> Canadian drugmaker Concordia Healthcare could be the next target for a tax inversion thanks to a tax rate the CEO says is in the single digits. Story

> Colorado biotech MiRagen Therapeutics has deepened its ties to French drugmaker Servier and raised $7 million. More

> California's Durect ($DRRX) has raised $20 million in debt financing. Release

Medical Device News

@FierceMedDev: Pharma company Merz to buy ultrasound company to strengthen beautification biz. Story | Follow @FierceMedDev

@StacyALawrence: Philips, Salesforce.com to create clinical, cloud-based platform. Story | Follow @StacyALawrence

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. More via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Hard verdict to swallow: New York high court shoots down NYC ban on super-sized sodas. More | Follow @EmilyWFierce

> FDA clears first robotic exoskeleton for patients with spinal cord injuries. Story

> Vagus nerve stimulator effective to prevent migraines, study says. Report

> Pharma company Merz to buy ultrasound company to strengthen beautification biz. Article

Pharma News

@FiercePharma: Top-read on FierceVaccines Thurs: CDC committee recommends AZ's FluMist over flu shot in children. Story | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bring out the confetti: 7 of 2013's launches will join Sovaldi, Tecfidera in blockbuster land. More | Follow @CarlyHFierce

> Eliquis scores DVT/PE recommendation in Europe. News

> Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar. More

> EU backs Roche's Avastin for hard-to-treat ovarian cancer. Article

> Ranbaxy's generic of Novartis blockbuster Diovan approved for launch. Story

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.